Overview
ANTX market data
Price History
ANTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.16 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.00 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.00 – $6.91 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $176.1 · P/B 0.59.
Company news
Guggenheim Initiates Coverage On AN2 Therapeutics with Buy Rating, Announces Price Target of $9Benzinga · Jul 20, 2026, 12:03 PM
8-K filing — AN2 Therapeutics, Inc. (ANTX)SEC EDGAR · Jun 4, 2026, 8:15 PM
AN2 Therapeutics Announces Results From Two Studies Evaluating Its Oral CPSF3 Inhibitor, AN2-502998, For The Treatment Of Chronic Chagas Disease; Parasites Eliminated With 28-Day Treatment In 100% Of Nonhuman PrimatesBenzinga · Jun 4, 2026, 11:20 AM
AN2 Therapeutics Announces Results From Two Studies Evaluating Oral CPSF3 Inhibitor, AN2-502998, For Treatment Of Chronic Chagas Disease Caused By Infection With Parasite T. CruziBenzinga · Jun 4, 2026, 11:15 AM
Leerink Partners Upgrades AN2 Therapeutics to Outperform, Announces $9 Price TargetBenzinga · May 14, 2026, 8:35 PM